Weight loss (GLP-1 programs)
US offer moved to branded GLP-1 drugs in Q1 2026. Compounded semaglutide remains available only on a limited scale.
The numbers
What it is
Weight loss programs that prescribe GLP-1 drugs. In March 2026 Hims agreed with Novo Nordisk to offer Ozempic and the Wegovy pill and injection, and to stop advertising compounded GLP-1s. Compounded semaglutide is still offered on a limited scale when a provider judges it clinically necessary.
Why it matters to the stock. Weight loss is a large part of the product mix behind higher revenue per subscriber. The move to branded drugs reduces regulatory exposure over compounding, but it adds drug costs and restructuring charges that weigh on margin.
News
Hims & Hers Q1 2026 net loss of $92 million; Q2 and full-year guidance set
Hims & Hers reported first-quarter 2026 revenue of $608.1 million, up 4%, and a net loss of $92.1 million, against net income a year earlier.
Hims & Hers to sell Novo Nordisk's Ozempic and Wegovy and drop compounded GLP-1 ads
Hims & Hers and Novo Nordisk agreed to sell Novo's branded Ozempic and Wegovy, including the Wegovy pill, on the Hims platform.
Novo Nordisk sues Hims & Hers for patent infringement over compounded semaglutide
Novo Nordisk filed a patent infringement suit against Hims & Hers, alleging that its compounded semaglutide products infringe US Patent 8,129,343.
Hims & Hers drops its compounded copy of Novo's Wegovy pill two days after launch
Hims announced a compounded semaglutide pill on February 5, 2026, priced as a low-cost alternative to Novo Nordisk's Wegovy pill.